PureTech Health plc (LON:PRTC – Get Free Report) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 129.42 and traded as low as GBX 122. PureTech Health shares last traded at GBX 122.58, with a volume of 287,786 shares.
Wall Street Analysts Forecast Growth
Separately, Peel Hunt restated a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of GBX 508.
Get Our Latest Report on PureTech Health
PureTech Health Trading Down 0.4%
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
See Also
- Five stocks we like better than PureTech Health
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
